Despite a global tendency for lower than average success rates from Phase I to approval in the challenging oncology and CNS areas, a recent Citeline study finds top Japanese pharma firms have relatively high rates in these two categories in the US. So what are the factors driving those differences?
The top 11 Japanese pharmaceutical firms have relatively higher R&D success rates in the US market in the areas of oncology and central nervous system (CNS), a new report from Citeline's Biomedtracker finds.
The research tracked past records for Phase I-III trials, revealing several major companies from Japan including Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co. Ltd. and Otsuka Holdings Co., Ltd
Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
